公司会议参与计划 - 公司管理层将参加2025年秋季三场行业会议 包括美国胃肠病学院年会(10月24-29日) 美国肝病研究协会年会(11月7-10日) 和美国药物科学家协会PharmSci 360会议(11月9-12日) [1][2] - 具体安排为：ACG会议10月26日15:30-16:30太平洋时间在凤凰城会议中心 AASLD会议11月10日13:00-14:00东部时间在华盛顿会议中心 AAPS会议在圣安东尼奥会议中心举行晚期突破海报展示 [3] 核心产品管线 - 主要临床资产TH104正通过505(b)2途径开发 用于军事人员和化学事件响应人员可能接触高效阿片类药物污染环境导致的呼吸和/或神经系统抑制 [4] - 扩展管线包括TH104用于原发性胆汁性胆管炎慢性瘙痒适应症 以及TH023用于治疗自身免疫性疾病 [4] - 公司拥有早期多特异性生物制剂平台 通过专有EpiClick技术针对多个实体瘤的独特表位 [4] 技术合作与定位 - 公司与OmniAb Inc签订许可协议 获得其抗体发现技术用于靶向特定疾病标志物 [4] - 公司定位为以患者为中心的创新领导者 致力于为股东创造长期价值 [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission file number 001-41210 THARIMMUNE, INC. (Exact name of registrant as specified in charter) | Delaware | 84-2642541 | | --- | --- | | (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission file number 001-41210 THARIMMUNE, INC. (Exact name of registrant as specified in charter) | Title of each class | Trading Symbol(s) | Name ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission file number 001-41210 THARIMMUNE, INC. (Exact name of registrant as specified in charter) | Delaware | 84-2642541 | | --- | --- | | (State or ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission file number 001-41210 THARIMMUNE, INC. (Exact name of registrant as specified in charter) | Delaware | 84-2642541 | | --- | --- | | (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission file number 001-41210 THARIMMUNE, INC. (Exact name of registrant as specified in charter) | Delaware | 84-2642541 | | --- | --- | | (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission file number 001-41210 THARIMMUNE, INC. (Exact name of registrant as specified in charter) | Delaware | 84-2642541 | | --- | --- | | (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission file number 001-41210 THARIMMUNE, INC. (Exact name of registrant as specified in charter) | Delaware | 84-2642541 | | --- | --- | | (State or ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to ___________ Commission File Number: 001-41210 THARIMMUNE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 84-2642541 (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to ___________ Commission File Number: 001-41210 HILLSTREAM BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 84-2642541 ( ...